AbCellera Biologics (ABCL) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
AbCellera Biologics insider trading at a glance (Oct 9, 2026): in the past 12 months, 4 insiders bought $2.7M and 0 sold $0 of ABCL stock on the open market, including a cluster buy that began Aug 12, 2026.
Get emailed when insiders cluster-buy stocks like ABCL
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ABCL insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $1.5M | 4 | — | 0 |
| Q2 2026 | $95K | 1 | — | 0 |
| Q1 2026 | $857K | 3 | — | 0 |
| Q4 2025 | $178K | 1 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 4 AbCellera Biologics Inc. insiders reported open-market purchases totaling $2.7M, while 0 insiders reported sales totaling $0. The most recent cluster buy began on Aug 12, 2026, when 3 insiders bought a combined $1.5M. Among insiders with enough purchase history to measure, John S. Montalbano (Director) has the highest Insider Score at 99.
ABCL earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 5, 2026 | +5.0% | None | +7.2%S&P -0.4% | +75.0% |
| May 11, 2026 | +29.4% | None | -5.5%S&P +0.1% | +6.5% |
| Feb 24, 2026 | -4.1% | None | +5.3%S&P +1.6% | +2.5% |
| Nov 6, 2025 | -15.9% | None | -16.6%S&P -1.0% | -9.0% |
| Aug 7, 2025 | -16.3% | None | +3.2%S&P +0.7% | -0.7% |
| May 8, 2025 | -20.2% | None | +1.0%S&P +0.6% | +20.2% |
| Feb 27, 2025 | -1.0% | None | -11.5%S&P -0.1% | -10.6% |
| Nov 4, 2024 | +1.9% | None | -0.4%S&P +1.0% | +4.8% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
ABCL stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 24SEC | Michael R HaydenDirector | Buy | 53,6131,373,397 held (+4%) | $10.64 | $570K | +17.9% | — |
| Aug 18SEC | John S. MontalbanoDirector | Buy | 10,000251,000 held (+4%) | $11.03 | $110K | +13.7% | 99 |
| Aug 14SEC | Michael R HaydenDirector | Buy | 46,3871,319,784 held (+4%) | $10.37 | $481K | +21.0% | — |
| Aug 14SEC | Andrew BoothCFO | Buy | 37,200482,800 held (+8%) | $10.32 | $384K | +21.6% | — |
| May 18SEC | John S. MontalbanoDirector | Buy | 20,000241,000 held (+9%) | $4.77 | $95K | +163.0% | 99 |
| Mar 2SEC | Thermopylae Holdings Ltd.10% Owner | Buy | 38,00056,134,097 held (+0%) | $3.44 | $131K | +264.7% | 97 |
| Feb 27SEC | Thermopylae Holdings Ltd.10% Owner | Buy | 177,45756,096,097 held (+0%) | $3.27 | $580K | +283.6% | 97 |
| Feb 27SEC | Andrew BoothCFO | Buy | 42,600195,600 held (+28%) | $3.42 | $146K | +266.8% | — |
| Nov 26SEC | John S. MontalbanoDirector | Buy | 50,000221,000 held (+29%) | $3.57 | $178K | +251.4% | 99 |
Insiders at AbCellera Biologics Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Michael R HaydenDirector | $1.1M | — | Aug 24, 2026 | — |
| Thermopylae Holdings Ltd.10% Owner | $711K | — | Mar 2, 2026 | 97 |
| Andrew BoothCFO | $530K | — | Aug 14, 2026 | — |
| John S. MontalbanoDirector | $384K | — | Aug 18, 2026 | 99 |
ABCL stock: common questions
Are AbCellera Biologics Inc. insiders buying ABCL stock?
In the past 12 months, 4 insiders reported open-market purchases of ABCL worth $2.7M. The latest was Director Michael R Hayden bought $570K of ABCL at $10.64 — largest purchase by this insider in our records.
Are AbCellera Biologics Inc. insiders selling ABCL stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ABCL's 52-week range?
Over the past year ABCL has traded between $2.78 and $14.82. It last closed at $12.54 on Oct 9, 2026.